Modality
Small Molecule
MOA
Cl18.2
Target
WRN
Pathway
Autophagy
Atopic DermRB
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
→ Sep 2027
Phase 2Current
NCT06308799
2,869 pts·Atopic Derm
2020-02→2027-09·Not yet recruiting
NCT07321537
1,898 pts·Atopic Derm
2018-01→2026-07·Completed
4,767 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-264mo awayPh2 Data· Atopic Derm
2027-09-221.5y awayPh2 Data· Atopic Derm
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Complet…
P2
Not yet…
Catalysts
Ph2 Data
2026-07-26 · 4mo away
Atopic Derm
Ph2 Data
2027-09-22 · 1.5y away
Atopic Derm
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06308799 | Phase 2 | Atopic Derm | Not yet recr... | 2869 | 6MWD |
| NCT07321537 | Phase 2 | Atopic Derm | Completed | 1898 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 |